查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1847913

驅蟲藥市場（依藥物類別、動物種類、給藥途徑、劑型及銷售管道）——2025-2032 年全球預測

Anthelmintic Drugs Market by Drug Class, Animal Type, Route Of Administration, Formulation, Sales Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年驅蟲藥市場規模將成長至 67.4 億美元，複合年成長率為 8.26%。

主要市場統計數據
基準年2024年 35.7億美元
預計2025年 38.6億美元
預測年份：2032年 67.4億美元
複合年成長率（%） 8.26%

全面說明驅蟲藥的治療重要性、臨床壓力以及影響人類和動物健康治療方法的商業性要求。

驅蟲藥是獸醫和人類寄生蟲疾病管理的基石，在動物健康、公共衛生和農業生產力方面帶來顯著效益。這些療法涵蓋多種針對線蟲、絛蟲和顫動蟲的化學類型和給藥方法，其合理應用對於維護動物福利和食品安全至關重要。臨床醫生、生產者和公共衛生官員日益面臨寄生蟲抗藥性不斷演變、監管預期不斷變化以及最佳化治療效果並最大程度降低環境和殘留問題的壓力等複雜因素的相互作用。

在此背景下，相關人員需要簡潔的、基於證據的分析來指導其臨床和商業優先事項。本報告整合了當前的科學趨勢、監管發展和分銷管道動態，以幫助決策者協調其開發平臺、籌資策略和上市舉措。透過將臨床背景與營運現實相結合，本報告為深入了解市場驅動力以及製造商、經銷商和政策制定者可用的戰術性選項奠定了基礎。

進化壓力、科學創新和監管的融合正在重塑驅蟲治療的商業策略和管理模式

驅蟲藥物領域正在發生重大變化，這得益於分子類別的創新、抗藥性模式的不斷增加以及監管和永續性考慮的融合。新的化學成分和製劑技術正在擴展治療套件，使其具有更長的藥效持續時間、更好的偏好以及替代的給藥方式，從而更好地滿足最終用戶的需求。同時，基因組監測和現場診斷揭示了異質性抗藥性的出現，這需要有針對性的管理計劃和針對特定部位的治療流程。

治療模式也在不斷調整，製造商投資於附加價值服務，例如診斷主導的治療建議和針對大規模畜牧養殖的批量供應解決方案。法律規範日益重視殘留監測、環境風險評估和嚴格的產品生命週期數據，從而推動更早、更整合的監管策略工作流程。這種轉變凸顯了市場參與企業需要擺脫以產品為中心的規劃，提供將治療效果與可證明的管理和永續性結合的綜合服務。因此，藥物開發商、診斷公司和分銷網路之間的夥伴關係正成為該領域競爭定位的核心特徵。

2025 年推出的貿易政策調整創造了持續的供應鏈和採購需求，影響製造決策和商業定價動態

美國自2025年起實施的關稅變化的累積影響，為整個驅蟲藥價值鏈的供應鏈最佳化、籌資策略和定價模式帶來了新的考量。進口關稅及相關貿易措施提高了某些來自國際製造地的活性原料藥和成品藥的到岸成本，迫使採購團隊重新評估供應商的多樣性，並加快替代製造商的資格認定。同時，分銷合作夥伴和動物用藥品批發商也重新評估了其庫存和對沖策略，以減輕利潤壓力並保持關鍵治療產品供應的連續性。

這些發展趨勢也促使企業認真審視其區域製造投資和近岸外包策略，以降低關稅波動風險，並提高對當地監管核准的應對力。擁有垂直整合和靈活契約製造能力的企業找到了穩定價格和交貨時間的機會，而規模較小的企業在與通路合作夥伴的談判中則面臨著日益複雜的局面。為此，商務團隊正在改進合約條款，探索關稅分類最佳化，並深化與海關和貿易顧問的合作，以確保合規性，同時確保客戶獲得必需品。

細緻的細分洞察，包括藥理類別、動物群、給藥途徑、製劑類型和管道行為，揭示商業化的目標機會

細分領域的動態揭示了差異化的臨床和商業性軌跡，需要針對不同的治療類別、動物群、給藥途徑、劑型和銷售管道製定有針對性的策略。在藥物類別中，該領域的特點是傳統的苯並咪唑酮類藥物，它們在許多方案中繼續充當骨幹藥物；咪唑並噻唑和四氫嘧啶類藥物，它們對特定寄生蟲群體具有互補的藥效動力學特性；以及大環內酯類藥物，因其頻譜活性和長效製劑而備受推崇。每類藥物都有不同的動態風險，需要製定管理計劃，使給藥方案與診斷數據一致。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 開發伊維菌素和奧克太爾聯合治療來對抗抗藥性土源性蠕蟲
  • 引入照護現場分子診斷技術快速檢測牲畜多重抗藥性蠕蟲感染疾病
  • 植物來源植物化學驅蟲劑作為水產養殖管理的永續替代品的出現
  • 在盤尾絲蟲病和淋巴絲蟲病共同流行的地區進行綜合性群眾性藥物管理宣傳活動
  • 投資奈米製劑技術以提高苯並咪唑驅蟲藥的生物有效性和功效
  • 旨在最大程度減少環境中藥物殘留的新型大環內酯類似物的監管核准途徑
  • 利用藥物基因體學數據擴展精準劑量演算法，以最佳化兒科族群的驅蟲治療

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章 驅蟲藥市場（依藥物類別）

  • 苯並咪唑
  • 咪唑並噻唑和四氫嘧啶
  • 大環內酯

第9章 驅蟲藥市場（依動物類型）

  • 伴侶動物
    • 貓
    • 狗
  • 食用動物
    • 牛
    • 家禽
    • 綿羊和山羊
    • 豬
  • 人類
    • 成人
    • 孩子們

第10章 驅蟲藥市場（依給藥途徑）

  • 口服
  • 腸外
  • 話題

第 11 章。按配方分類的驅蟲藥市場

  • 注射
  • 口服懸浮液
  • 藥片

第 12 章 驅蟲藥市場（依銷售管道）

  • 網路藥局
  • 零售藥局
  • 獸藥經銷商
  • 獸醫醫院和診所

第13章 各地區驅蟲藥市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章 驅蟲藥市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。各國驅蟲藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Merck & Co., Inc.
    • Boehringer Ingelheim GmbH
    • Ceva Sante Animale SA
    • Virbac SA
    • Dechra Pharmaceuticals PLC
    • Norbrook Laboratories Limited
    • Aden Healthcare
    • Bayer AG
    • Cipla Limited
    • Anikem Laboratories
Product Code: MRR-FB6C9E792F81

The Anthelmintic Drugs Market is projected to grow by USD 6.74 billion at a CAGR of 8.26% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.57 billion
Estimated Year [2025] USD 3.86 billion
Forecast Year [2032] USD 6.74 billion
CAGR (%) 8.26%

Comprehensive orientation to anthelmintic therapeutic importance, clinical pressures, and commercial imperatives shaping treatment approaches across human and animal health

Anthelmintic drugs remain a cornerstone of veterinary and human parasitic disease management, delivering measurable benefits across animal health, public health, and agricultural productivity. The therapeutic category encompasses a range of chemotypes and administration approaches that target nematodes, cestodes, and trematodes, and their appropriate deployment is critical to sustaining animal welfare and food safety. Clinicians, producers, and public health authorities increasingly face a complex interplay of evolving parasite resistance, shifting regulatory expectations, and pressure to optimize therapeutic efficacy while minimizing environmental and residue concerns.

Against this backdrop, stakeholders require concise, evidence-driven analysis that frames clinical and commercial priorities. This report synthesizes current scientific developments, regulatory trends, and distribution channel dynamics to enable decision-makers to align research and development pipelines, procurement strategies, and market access initiatives. By integrating clinical context with operational realities, this introduction sets the stage for deeper examination of market-moving forces and tactical options available to manufacturers, distributors, and policy makers.

Evolutionary pressures, scientific innovations, and regulatory convergence are reshaping commercial strategies and stewardship models across anthelmintic therapeutics

The landscape for anthelmintic drugs is undergoing transformative shifts driven by innovation in molecular classes, rising resistance patterns, and the convergence of regulatory and sustainability agendas. Novel chemistries and formulation technologies are expanding the therapeutic toolkit, enabling longer duration of action, improved palatability, and alternative delivery modalities that better match end-user needs. Concurrently, genomic surveillance and field-level diagnostics are revealing heterogeneous resistance emergence that requires targeted stewardship programs and region-specific treatment algorithms.

Commercial models are adapting as well, with manufacturers investing in value-added services such as diagnostic-driven treatment recommendations and bundled supply solutions for large livestock operations. Regulatory frameworks are increasingly emphasizing residue monitoring, environmental risk assessment, and rigorous product lifecycle data, prompting earlier and more integrated regulatory strategy workstreams. These shifts underscore the need for market participants to pivot from product-centric plans to integrated service offerings that combine therapeutic efficacy with demonstrable stewardship and sustainability credentials. As a result, partnerships between pharmaceutical developers, diagnostic firms, and distribution networks are becoming a central feature of competitive positioning in this sector.

Trade policy adjustments introduced in 2025 have created sustained supply chain and sourcing imperatives that influence manufacturing decisions and commercial pricing dynamics

The cumulative impact of tariff changes initiated in the United States during 2025 has introduced new considerations for supply chain optimization, sourcing strategy, and pricing models across the anthelmintic drugs value chain. Import duties and related trade measures have increased landed costs for certain active pharmaceutical ingredients and finished formulations sourced from international manufacturing hubs, prompting procurement teams to reassess supplier diversity and to accelerate qualification of alternative manufacturers. In parallel, distribution partners and veterinary wholesalers have revisited inventory and hedging practices to mitigate margin pressure and to preserve continuity of supply for critical therapeutic lines.

These developments have also incentivized a deliberate reconsideration of regional manufacturing investments and nearshoring strategies to reduce exposure to tariff volatility and to enhance responsiveness to local regulatory approvals. Firms with greater vertical integration or flexible contract manufacturing capabilities have found opportunities to stabilize pricing and delivery, while smaller companies face heightened negotiation complexity with channel partners. In response, commercial teams are refining contractual terms, exploring tariff classification optimizations, and deepening collaboration with customs and trade advisors to navigate compliance while preserving customer access to essential products.

Granular segment insights across pharmacological classes, animal cohorts, administration routes, formulation types, and channel behaviors reveal targeted opportunities for commercialization

Segment-level dynamics reveal differentiated clinical and commercial trajectories that require targeted strategies across drug classes, animal cohorts, administration routes, formulation types, and sales channels. Based on drug class, the field is characterized by traditional benzimidazoles which continue to serve as backbone agents in many protocols, imidazothiazoles and tetrahydropyrimidines that offer complementary pharmacodynamic profiles for specific parasite groups, and macrocyclic lactones which are prized for broad-spectrum activity and long-acting formulations. Each class presents distinct resistance risks and requires stewardship planning that aligns dosing regimens with diagnostic data.

Based on animal type, the commercial and clinical landscapes diverge meaningfully. Companion animals prioritize safety, taste, and convenient administration, with companion animal cohorts further differentiated into cats and dogs that have unique tolerability and product preference patterns. Food producing animals focus on production economics and residue compliance, with cattle, poultry, sheep and goat, and swine exhibiting varied parasite exposure and management frameworks that drive treatment frequency and product choice. The human segment requires rigorous safety and regulatory oversight with adult and pediatric subpopulations demanding tailored dosing and formulation considerations. Based on route of administration, product selection and adoption hinge on oral therapies favored for ease of use, parenteral options chosen for bioavailability and controlled delivery, and topical preparations selected for localized application and owner convenience.

Based on formulation, injectable preparations deliver reliable plasma concentrations for systemic infections, oral suspensions meet needs for flexible dosing across weight ranges, and tablets remain a staple where stability and dosing accuracy are paramount. Based on sales channel, adoption and access are shaped by online pharmacies that expand reach and convenience, retail pharmacies that serve human and companion animal markets, veterinary distributors that bridge manufacturers and clinical end users, and veterinary hospitals and clinics that serve as primary points of care and influence repeat purchase behavior. Understanding these intersecting segment dynamics enables more precise product positioning, pricing strategies, and lifecycle management decisions that reflect both clinical performance and customer preferences.

Regional epidemiology, regulatory diversity, and distribution maturity across the Americas, EMEA, and Asia-Pacific create distinct pathways for market access and product adoption

Regional dynamics in anthelmintic therapeutics vary by epidemiology, regulatory requirements, and distribution infrastructure, shaping differentiated priorities for manufacturers and suppliers. The Americas region exhibits mature distribution frameworks, widespread veterinary practice networks, and increasing demand for innovation in companion animal care alongside large-scale livestock production systems that prioritize productivity and residue compliance. In this region, integrated service models and diagnostic-driven treatment protocols are gaining traction to optimize therapeutic outcomes and to address resistance concerns.

Europe, Middle East & Africa present a complex mosaic of market conditions where stringent regulatory oversight in parts of Europe coexists with variable access and infrastructure constraints across other countries. This diversity requires adaptable market access strategies that balance regulatory rigor, affordability, and targeted education initiatives to support appropriate use. In several countries within this geography, environmental considerations and sustainability reporting are becoming prominent purchase criteria, influencing formulation development and post-market monitoring.

Asia-Pacific encompasses high-growth livestock sectors, an expanding companion animal market, and diverse regulatory regimes that range from highly structured to evolving frameworks. Rapid adoption of digital distribution channels and a growing appetite for value-added services are notable across the region. Manufacturers operating here must navigate heterogeneous reimbursement and procurement landscapes while leveraging regional manufacturing capacity to enhance supply resilience and to meet local demand patterns.

Competitive landscape shaped by legacy pharmaceutical strengths, specialized innovation, and collaborative models that integrate diagnostics, manufacturing flexibility, and channel influence

Competitive dynamics among leading organizations in the anthelmintic space reflect a mix of legacy pharmaceutical capabilities, targeted innovation investments, and strategic partnerships. Established animal health pharmaceutical firms continue to leverage extensive clinical trial experience, regulatory know-how, and deep distribution networks to sustain presence in both livestock and companion animal segments. At the same time, specialist biotech and smaller innovators are advancing novel molecules, reformulations, and diagnostic-integrated offerings that aim to address resistance hotspots and to create differentiated value propositions.

Partnerships between diagnostics providers and therapeutic developers are emerging as a critical vector for competitive advantage, as real-world diagnostic data enables more precise treatment algorithms and supports stewardship narratives. Contract manufacturing organizations with flexible capacity and quality systems are increasingly strategic allies for companies seeking to scale production or to diversify geographic sourcing. Additionally, distributors and veterinary service networks that invest in training and digital engagement are gaining influence over prescribing patterns and can accelerate uptake of new products through bundled service models and clinician education initiatives.

Actionable priorities for manufacturers and distributors to align therapeutic innovation, stewardship programs, and supply resilience with channel-specific commercialization tactics

Industry leaders should pursue a multilayered approach that aligns product innovation with stewardship, supply resilience, and channel-centric commercialization. Prioritizing diagnostic-enabled treatment paradigms will both extend therapeutic lifespans and create opportunities for premium service offerings; integrating diagnostic data into commercial value propositions can distinguish products in crowded therapeutic classes. Concurrently, investing in formulation versatility-such as palatable oral suspensions for companion animals and extended-release injectables for livestock-will improve adherence and meet diverse clinical needs.

From a supply perspective, diversifying sourcing through regional manufacturing partnerships and qualified contract manufacturers can reduce exposure to tariff and logistics volatility while shortening lead times. Commercially, companies should develop tailored go-to-market strategies for different channels, including omnichannel approaches for retail and online pharmacies, and service bundles for veterinary hospitals and distributors that incentivize stewardship-aligned prescribing. Finally, embedding environmental risk assessments and residue management into product lifecycle planning will address regulator and customer expectations, supporting long-term market acceptance and license-to-operate objectives.

Robust mixed-methods approach combining literature synthesis, primary expert interviews, and scenario mapping to ensure transparent and actionable market insights

The research synthesis underpinning these insights draws on a mixed-methods approach that combines systematic literature review, primary qualitative interviews, and structured stakeholder engagement. The literature review surveyed peer-reviewed clinical studies, regulatory guidance documents, and technical reports to capture contemporary scientific and safety considerations. Primary inputs were gathered through confidential interviews with veterinarians, pharmacovigilance experts, hospital procurement leads, contract manufacturers, and trade advisors to surface operational challenges and real-world adoption drivers.

Analytical techniques included cross-sectional thematic analysis of qualitative data to identify recurring market signals, triangulation of regulatory trends to assess evolving compliance expectations, and scenario mapping to evaluate the implications of trade policy shifts and resistance emergence. Data quality was maintained through source triangulation and expert validation rounds. The methodology emphasizes transparency in assumptions and traceability of insights, enabling readers to understand the evidence base and to adapt findings to their organization's strategic context.

Synthesis of strategic imperatives highlighting stewardship, innovation, and supply chain adaptability as the foundation for sustainable success in anthelmintic therapeutics

In conclusion, the anthelmintic drugs domain is at an inflection point where clinical necessity intersects with commercial and regulatory complexity. The interplay of emerging resistance, novel formulation opportunities, and changing trade dynamics necessitates proactive strategies that prioritize diagnostic integration, stewardship, and supply chain diversification. Regional variation in epidemiology and regulatory regimes requires bespoke market approaches that reflect local priorities while preserving global coherence in product positioning and evidence generation.

Organizations that harmonize scientific rigor with flexible commercial models will be best positioned to deliver both clinical value and sustainable growth. By focusing on targeted innovation, strengthened distribution partnerships, and data-driven stewardship, stakeholders can navigate near-term disruptions and build resilient pathways for long-term therapeutic relevance. These conclusions provide a pragmatic blueprint for aligning R&D, regulatory, and commercial activities to meet the evolving needs of clinicians, producers, and public health decision-makers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Development of ivermectin-oxantel combination therapies to combat resistant soil-transmitted helminths
  • 5.2. Adoption of point-of-care molecular diagnostics for rapid detection of multi-drug resistant helminth infections in livestock
  • 5.3. Emergence of plant-derived phytochemical anthelmintics as sustainable alternatives in aquaculture management
  • 5.4. Implementation of integrated mass drug administration campaigns targeting onchocerciasis and lymphatic filariasis co-endemic regions
  • 5.5. Investment in nanoformulation techniques to enhance bioavailability and efficacy of benzimidazole-based anthelmintics
  • 5.6. Regulatory approval pathways for novel macrocyclic lactone analogues designed to minimize environmental drug residues
  • 5.7. Expansion of precision dosing algorithms using pharmacogenomic data to optimize anthelmintic therapy in pediatric populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anthelmintic Drugs Market, by Drug Class

  • 8.1. Benzimidazoles
  • 8.2. Imidazothiazoles And Tetrahydropyrimidines
  • 8.3. Macrocyclic Lactones

9. Anthelmintic Drugs Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
  • 9.2. Food Producing Animals
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep And Goat
    • 9.2.4. Swine
  • 9.3. Human
    • 9.3.1. Adults
    • 9.3.2. Pediatric

10. Anthelmintic Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Anthelmintic Drugs Market, by Formulation

  • 11.1. Injectable
  • 11.2. Oral Suspension
  • 11.3. Tablet

12. Anthelmintic Drugs Market, by Sales Channel

  • 12.1. Online Pharmacies
  • 12.2. Retail Pharmacies
  • 12.3. Veterinary Distributors
  • 12.4. Veterinary Hospitals And Clinics

13. Anthelmintic Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anthelmintic Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anthelmintic Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck & Co., Inc.
    • 16.3.2. Boehringer Ingelheim GmbH
    • 16.3.3. Ceva Sante Animale S.A.
    • 16.3.4. Virbac S.A.
    • 16.3.5. Dechra Pharmaceuticals PLC
    • 16.3.6. Norbrook Laboratories Limited
    • 16.3.7. Aden Healthcare
    • 16.3.8. Bayer AG
    • 16.3.9. Cipla Limited
    • 16.3.10. Anikem Laboratories

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTHELMINTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTHELMINTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTHELMINTIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY IMIDAZOTHIAZOLES AND TETRAHYDROPYRIMIDINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SHEEP AND GOAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ORAL SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL ANTHELMINTIC DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 317. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 320. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 321. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 322. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY FOOD PRODUCING ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 323. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 324. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 327. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 328. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 329. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. ASEAN ANTHELMINTIC DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. GCC ANTHELMINTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. GCC ANTHELMINTIC DR